Itepekimab

Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) [1][2][3][4].

Product Specifications

CAS Number

[2226742-52-3]

Product Name Alternative

REGN-3500; SAR-440340

UNSPSC

12352203

Target

Interleukin Related; NF-κB

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/itepekimab.html

Purity

99.40

Solubility

10 mM in DMSO

Smiles

[Itepekimab]

Molecular Weight

(144.64 kDa)

References & Citations

[1]Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385 (18) :1656-1668.|[2]Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15 (2) :384-395.|[3]Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9 (11) :1288-1298.|[4]Asrat S, et al. Itepekimab Binds to IL-33 With High Affinity, Prevents the Formation of IL-33/ST2/IL-1RAcP Signaling Complex and Blocks Mediators of Airway Inflammation[M]//C13. CYTOKINES: CYTOKINES IN THE AIRWAYS. American Thoracic Society, 2023: A4478-A4478.